1h Free Analyst Time
The neuromuscular disease therapeutics market is forecasted to grow by USD 13.72 billion during 2024-2029, accelerating at a CAGR of 14.6% during the forecast period. The report on the neuromuscular disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by novel approvals for neuromuscular disease therapeutics, increasing need for newborn screening tests, and huge unmet need for neuromuscular disease therapeutics.
The neuromuscular disease therapeutics market is segmented as below:
By End-user
- Hospitals
- Clinics
- Others
By Type
- Biologics
- Small molecules
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the neuromuscular disease therapeutics market covers the following areas:
- Neuromuscular Disease Therapeutics Market sizing
- Neuromuscular Disease Therapeutics Market forecast
- Neuromuscular Disease Therapeutics Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by End-user
9 Market Segmentation by Type
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global neuromuscular disease therapeutics market: AbbVie Inc., Aquestive Therapeutics Inc, argenx SE, AstraZeneca Plc, Biogen Inc., CuraVac, F. Hoffmann La Roche Ltd., Grifols SA, Merck and Co. Inc., Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is technological advances in neuromuscular disease therapy."
According to the report, one of the major drivers for this market is the novel approvals for neuromuscular disease therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aquestive Therapeutics Inc
- argenx SE
- AstraZeneca Plc
- Biogen Inc.
- CuraVac
- F. Hoffmann La Roche Ltd.
- Grifols SA
- Merck and Co. Inc.
- Nippon Shinyaku Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Roivant Sciences Ltd.
- Santhera Pharmaceuticals Holding AG
- Sarepta Therapeutics Inc.
- Takeda Pharmaceutical Co. Ltd.
